Congress Presentations

Stay informed about the latest scientific and medical research from Axsome.

Filter

Sort

AMCP Nexus 2024

Las Vegas, NV | October 14 - 17, 2024

AXS-05 | Major Depressive Disorder

Real-World Auvelity® (AXS-05) Patient Characteristics in Major Depressive Disorder

View / Download

AXS-05 | Major Depressive Disorder

Dr. Andrew Muzyk, PharmD describes the “Real-World Auvelity® (AXS-05) Patient Characteristics in Major Depressive Disorder” Poster

View

AXS-05 | Major Depressive Disorder

Auvelity® (AXS-05) in Major Depressive Disorder: Pooled Data from Two Six-Week Controlled Trials (GEMINI and ASCEND)

View / Download

Migraine

Combined Efficacy and Safety of AXS-07 (MoSEICTM Meloxicam and Rizatriptan) in Two Phase 3 Clinical Trials

View / Download

This site contains scientific information about investigational compounds and/or information about products and/or uses that have not been approved by the US Food and Drug Administration. The safety and efficacy of investigational products and/or investigational uses of approved products has not been established and such investigational products/uses have not and may not be approved for marketing by any health authority.

AXSOME, AUVELITY, SUNOSI, SYMBRAVO and their logos are trademarks or registered trademarks of Axsome Therapeutics, Inc. or its affiliates. Other trademarks are property of their respective owners.